Equashield, founded in 2009 and headquartered in Port Washington, New York, is a leading medical device company specializing in closed-system transfer devices (CSTDs) for the safe handling of hazardous drugs. The company raised $300 million in its Series D round in October 2022, led by Nordic Capital, reaching a $1.3 billion valuation. With 59 employees, Equashield develops advanced solutions like EQUASHIELD Pro, an automated compounding robot enhancing precision, safety, and efficiency in drug preparation.